• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Yingying, LI Ruiyan, CHEN Huan, ZHANG Yubin. Development and application of drugs targeting the innate and adaptive immune system in the colon[J]. Journal of China Pharmaceutical University, 2016, 47(4): 388-396. DOI: 10.11665/j.issn.1000-5048.20160402
Citation: CHEN Yingying, LI Ruiyan, CHEN Huan, ZHANG Yubin. Development and application of drugs targeting the innate and adaptive immune system in the colon[J]. Journal of China Pharmaceutical University, 2016, 47(4): 388-396. DOI: 10.11665/j.issn.1000-5048.20160402
shu

Development and application of drugs targeting the innate and adaptive immune system in the colon

More Information
    Graphical Abstract
    • Abstract
  • Recent advances in immunology and genetics have verified that the innate immune and adaptive immune responses that mediated by T cells, have been considered to play an important role in inducing inflammatory bowel disease. It’s difficult to cure the disease due to the complexity of the disease. However, the development and application of medicine, which target the immune response in the colon, attract great attention in recent years. In present, there are two types of targeting drugs in the intestinal immune systems: one of them targets the intestinal innate immune system, which includes targeting signal transduction, signal molecule and lymphocytes while the other targets adaptive immune system that includes inhibition of intenstinal T cell activation, differentiation and regulation of T cell cytokines and balance of T cell. This article mainly gives a comprehensive overview in four aspects, which include the intestinal innate immune response, adaptive immune response, drugs targeting in the intestinal innate and adaptive immune response. Furthermore, research directions are also pointed out in the review.
    • FullText(HTML)
    • References (59)
  • [1]
    Colgan SP.Inflammatory bowel disease therapies: US,8962530[P].2015-02-24[2016-05-22] .
    [2]
    Mysha M,Siegel CA.Do inflammatory bowel disease therapies cause cancer[J]?Inflamm Bowel Dis,2013,19(6):1306-1321.
    [3]
    Das S,Rachagani S,Sheinin Y,et al.Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer[J].Oncogene,2016,35(20):2645-2654.
    [4]
    Salim SY,Soderholm JD.Importance of disrupted intestinal barrier in inflammatory bowel diseases[J].Inflamm Bowel Dis,2011,17:362-381.
    [5]
    Uehara A,Fujimoto Y,Fukase K,et al.Various human epithelial cells express functional Toll-like receptors,NOD1 and NOD2 to produce anti-microbial peptides,but not proinflammatory cytokines[J].Mol Immunol,2007,44(12):3100-3111.
    [6]
    Donnarumma G,Paoletti I,Fusco A,et al.β-Defensins:work in Progress[J].Adv Exp Med Biol,(2016-02-11)[2016-05-22] .http://www.ncbi.nlm.nih.gov/pubmed/26864271.
    [7]
    Liu TC,Gurram B,Baldridge M,et al.O-011 paneth cell phenotypes define a subtype of pediatric crohn′s disease through alterations in host-microbial interactions[J].Inflamm Bowel Dis,2016,22(Suppl 1):S4.
    [8]
    Jang JH,Shin HW,Lee JM,et al.An overview of pathogen recognition receptors for innate immunity in dental pulp[J].Mediators Inflamm,2015,2015:1-12.
    [9]
    Salem M,Seidelin JB,Eickhardt S,et al.Species-specific engagement of human NOD2 and TLR signaling upon intracellular bacterial infection:role of Crohn′s associated NOD2 gene variants[J].Clin Exp Immunol,2014,179(3):426-434.
    [10]
    Folkard DL,Marlow G,Mithen RF,et al.Effect of Sulforaphane on NOD2 via NF-κB:implications for crohn’s disease[J].J Inflamm,2015,12(1):1- 6.
    [11]
    Zaki MH,Boyd KL,Vogel P,et al.The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis[J].Immunity,2010,32(3):379-391.
    [12]
    Sun Y,Zhao Y,Yao J,et al.Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation[J].Biochem Pharmacol,2015,94(2):142-154.
    [13]
    Yeretssian G.Effector functions of NLRs in the intestine:innate sensing,cell death,and disease[J].Immunol Res,2012,54(1/2/3):25-36.
    [14]
    Ishizuka IE, Chea S, Gudjonson H, et al. Single-cell analysis defines the divergence between the innate lymphoid cell lineage and lymphoid tissue-inducer cell lineage[J].Nat Immunol,2016,17(3):269-276.
    [15]
    Yazdani R,Sharifi M,Shirvan AS,et al.Characteristics of innate lymphoid cells(ILCs)and their role in immunological disorders(an update)[J].Cell Immunol,2015,298(1/2):66-76.
    [16]
    Peng H, Tian ZG. Advances in innate lymphoid cells[J].J Immunol(中国免疫学杂志),2015,(2):145-150.
    [17]
    Leung JM,Loke P.A role for IL-22 in the relationship between intestinal helminths,gut microbiota and mucosal immunity[J].Int J Parasitol,2012,3(3/4):253-257.
    [18]
    Buonocore S,Ahern PP,Uhlig HH,et al.Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology[J].Nature,2010,464(7293):1371-1375.
    [19]
    Chen L,He Z,Slinger E,et al.IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology[J].Mucosal Immunol,2015,8(2):390-402.
    [20]
    Hirahara K,Nakayama T.CD4+ T cell subsets in inflammatory diseases:beyond the Th1/Th2 paradigm[J].Int Immunol,2016,28(4):163-171.
    [21]
    Annunziato F,Romagnani C,Romagnani S.The 3 major types of innate and adaptive cell-mediated effector immunity[J].J Allergy Clin Immunol,2015,135(3):626-635.
    [22]
    Yamada A,Arakaki R,Saito M,et al.Role of regulatory T cell in the pathogenesis of inflammatory bowel disease[J].World J Gastroenterol,2016,22(7):2195-2205.
    [23]
    Rovedatti L,Kudo T,Biancheri P,et al.Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease[J].Gut 2009,58(12):1629-1636.
    [24]
    Wilson MS,Ramalingam TR,Rivollier A,et al.Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity[J].Gastroenterology,2011,140(1):254-264.
    [25]
    Bernardo D,Vallejo-Díez S,Mann ER,et al.IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate[J].Eur J Immunol,2012,42(5):1337-1353.
    [26]
    Bauquet AT,Jin H,Paterson AM,et al.The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells[J].Nat Immunol,2009,23(2):167-175.
    [27]
    Bank S,Andersen PS,Burisch J,et al.Polymorphisms in the Toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a danish cohort[J].PLoS One,2015,10(12):1-14.
    [28]
    Ivanov II,Atarashi K,Manel N,et al.Induction of intestinal Th17 cells by segmented filamentous bacteria[J].Cell,2009,139(3):485-498.
    [29]
    Coccia M,Harrison OJ,Schiering C,et al.IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+)Th17 cells[J].J Exp Med,2012,209(9):1595-1609.
    [30]
    Liu W,Guo WJ,Guo LL,et al.Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response[J].Int Immunopharmacol,2014,20(2):337-345.
    [31]
    Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn′s disease[J].Gastroenterology,2005,128(3):687-694.
    [32]
    Kastirr I,Maglie S,Paroni M et al.IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells[J].J Immunol,2014,193(7):3322-3331.
    [33]
    Shimazu Y,Nishikawa H.Suppression of tumor antigen-specific T cell immune responses by regulatory T cells[J].Gan To Kagaku Ryoho,2014,41(9):1057-1061.
    [34]
    Fahlen L,Read S,Gorelik L,et al.T cells that cannot respond to TGF-β escape control by CD4(+)CD25(+)regulatory T cells[J].J Exp Med,2005,201(5):737-746.
    [35]
    Fantini MC,Rizzo A,Fina D,et al.Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression[J].Gastroenterology,2009,136(4):1308-1316.
    [36]
    Kleinewietfeld M,Hafler DA.The plasticity of human Treg and Th17 cells and its role in autoimmunity[J].Semin Immunol,2013,25(4):305-312.
    [37]
    Biancheri P,Di Sabatino A,Corazza GR,et al.Proteases and the gut barrier[J].Cell Tissue Res,2013,351(2):269-280.
    [38]
    Heller F,Fuss IJ,Nieuwenhuis EE,et al.Oxazolone colitis,a Th2 colitis model resembling ulcerative colitis,is mediated by IL-13-producing NK-T cells[J].Immunity,2002,17(5):629-638.
    [39]
    Kawalec P,Mikrut A,Wi'sniewska N,et al.Tumor necrosis factor-α antibodies(infliximab,adalimumab and certolizumab)in Crohn′s disease:systematic review and meta-analysis[J].Arch Med Sci,2013,9(5):765-779.
    [40]
    Louis E, Löfberg R, Reinisch W, et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn′s disease:results from the CARE trial[J].J Crohns Colitis,2013,7(1):34-43.
    [41]
    Liu LL,Mao YY,Gao LB.Analysis of global hot drug targets in 2014 —IL-6-targeted drugs[J].Prog Pharm Sci(药学进展),2015,39(11):870-873016,22(3):107-111.dmyre C,Knittel T,et al.DOP004 Induction of IL-10 positive cells in the colon mucosa of ulcerative colitis patients by the TLR-9 agonist DIMS0150[J].J Crohns Colitis,2014,8(10):S16.
    [42]
    Zeng ZJ, Zhan LL, Liao H, et al. Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/NF-κB signaling pathway[J].Planta Med,2012,79(2):102-109.
    [43]
    Xu YQ.Effects of Jiuxieling granules on the expression of TLR4 and NF-κB p65 and inflammatory cytokines on ulcerative colitis model rats of the spleen and kidney yang deficiency(久泻灵颗粒对脾肾阳虚型溃疡性结肠炎模型大鼠TLR4、NF-κB p65及炎性细胞因子表达的影响)[D].Lanzhou:Gansu College Traditional Chinese Medicine,2015.
    [44]
    Toshifumi H,Yoshihide F.Biological therapies for inflammatory bowel disease[J].J Gastroenterol,2013,37(14):43-43.
    [45]
    Sun Y,Zhang X,Li HY,et al.Treatment effects of wumei pill on rats with ulcerative colitis and the mechanisms[J].Mil Med J South China(华南国防医学杂志),2013,27(1):5-8.
    [46]
    Wang BT,Zhang QF,Qiu XF,et al.The intervention mechanism research of macrophage migration inhibitory factor monoclonal antibody on ulcerative colitis mice[J].Acta Universitatis Medicinalis Anhui(安徽医科大学学报),2016,51(1):31-35.
    [47]
    Sandborn WJ,Colombel J,Sands BE,et al.Abatacept for Crohn′s disease and ulcerative colitis[J].Gastroenterology,2012,143(1):62-69(e4).
    [48]
    Reinisch W,Hommes DW,Van Assche G,et al.A dose escalating,placebo controlled,double blind,single dose and multidose,safety and tolerability study of fontolizumab,a humanised anti-interferon γ antibody,in patients with moderate to severe Crohn′s disease[J].Gut,2006,55(8):1138-1144.
    [49]
    Reinisch W, Panés J, Khurana S, et al. Anrukinzumab,an anti-interleukin 13 monoclonal antibody,in active uc efficacy and safety from a phase II randomised multicentre study[J].Gut,2015,64(6):894-900.
    [50]
    Danese S,Rudziński J,Brandt W,et al.Tralokinumab for moderate-to-severe UC:a randomised,double-blind,placebo-controlled,phase IIa study[J].Gut,2015,64(2):243-249.
    [51]
    Herrlinger KR,Diculescu MM,Fellermann K,et al.Efficacy,safety and tolerability of vidofludimus in patients with inflammatory bowel disease:the ENTRANCE study[J].J Crohns Colitis,2013,7(8):636-643.
    [52]
    Simon EG,Ghosh S,Iacucci M,et al.Ustekinumab for the treatment of Crohn′s disease:can it find its niche[J]?Therap Adv Gastroenterol,2016,9(1):26-36.
    [53]
    Wang GQ,Wei WH,Yang J.Effects of Gancao Xiexin decoction on serum levels of IL-17 and IL-23 in patients with ulcerative colitis[J].J Nanjing Univ Tradit Chin Med(南京中医药大学学报),2016,32(1):25-28.
    [54]
    Schreiber S,Fedorak RN,Nielsen OH,et al.Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn′s disease.Crohn′s disease IL-10 cooperative study group[J].Gastroenterology,2000,119(6):1461-1472.
    [55]
    Lai JY,Hao LP,Song SY.Clinical efficacy of bifidobacteria triple viable capsule and its effects on the levels of CD4+ CD25+ regulatory T cells and IL-10 in patients with ulcerative colitis[J].Hainan Med J(海南医学),2016,27(1):40-42.
    [56]
    Hanai H,Sugimoto K.Curcumin has bright prospects for the treatment of inflammatory bowel disease[J].Curr Pharm Des,2009,15(18):2087-2094.
    [57]
    Xie F.Adjuvant effects of different extract fractions of Atractylodes macrocephala Koidz(白术不同提取物免疫佐剂作用的研究)[D].Hangzhou:Zhejiang University,2012.
    [58]
    Li C,Xi Y,Shan L,et al.Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation[J].Mol Immunol,2015,67(2 Pt B):444-454.
    [59]
    Liu RY,Xu R,Huang MF,et al.Mechanism of Sishen Wan in regulating balance of T lymphocyte subsets and Treg /Th17 in colitis rats[J].Chin J Exp Tradit Med Formulae(中国实验方剂学杂志),2016,22(3):107-111.
    • Related Articles

  • Related Articles

    [1]MU Yao, ZHAO Huimin, LIU Haochen, LIU Xiaoquan. Advances in drug development for Alzheimer’s disease[J]. Journal of China Pharmaceutical University, 2024, 55(6): 816-825. DOI: 10.11665/j.issn.1000-5048.2024010202
    [2]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [3]ZHANG Danfeng, JIAO Yu, LIU Yong, ZHANG Yanmin, ZHANG Zhimin, LU Tao. Progress of small molecule anti-tumor covalent drugs[J]. Journal of China Pharmaceutical University, 2017, 48(1): 1-7. DOI: 10.11665/j.issn.1000-5048.20170101
    [4]HE Wei, QI Haixia, DONG Lei, ZHANG Junfeng. Research advances in drug delivery system targeting immune system[J]. Journal of China Pharmaceutical University, 2015, 46(5): 513-520. DOI: 10.11665/j.issn.1000-5048.20150501
    [5]YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419
    [6]WANG Shu, ZHANG Zhenhai, GU Dongfei, ZHOU Jianping, LYV Huixia. Advances of exosomes as a new drug delivery system[J]. Journal of China Pharmaceutical University, 2014, 45(2): 247-252. DOI: 10.11665/j.issn.1000-5048.20140221
    [7]Development of drug for Alzheimer′s disease[J]. Journal of China Pharmaceutical University, 2010, 41(5): 395-400.
    [8]Application of pharmacometrics in drug development and therapeutic drug monitoring[J]. Journal of China Pharmaceutical University, 2010, 41(1): 91-96.
    [9]Application of Genechip Technology in Drug Discovery and Development[J]. Journal of China Pharmaceutical University, 2001, (2): 1-6.
    [10]Advances and Prospects of Drug Discovery and Development Zhang Yihua, Peng Sixun, Hua Weiyi[J]. Journal of China Pharmaceutical University, 1999, (2): 75-80.

Catalog

    Get Citation
    PDF
    XML
    Article views (1083) PDF downloads (1963) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：319008

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return